Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders

Christopher J. McDougle, Kimberly A. Stigler, Craig A. Erickson, David J. Posey

Research output: Contribution to journalReview article

89 Scopus citations

Abstract

Atypical antipsychotics are emerging as the first-line pharmacologic treatment for irritability (i.e., aggression, self-injurious behavior, and severe tantrums) in children and adolescents with autistic and other pervasive developmental disorders. Results from placebo-controlled and open-label studies of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole in this subject population are reviewed. Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalJournal of Clinical Psychiatry
Volume69
Issue numberSUPPL. 4
StatePublished - 2008

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders'. Together they form a unique fingerprint.

  • Cite this

    McDougle, C. J., Stigler, K. A., Erickson, C. A., & Posey, D. J. (2008). Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. Journal of Clinical Psychiatry, 69(SUPPL. 4), 15-20.